The management of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer continues to evolve, with endocrine therapy forming the cornerstone of treatment. Clinicians face ongoing challenges in optimising treatment sequences and identifying patients who will benefit most from novel agents, particularly in the context of acquired resistance. Upcoming presentations at the American Society of Clinical Oncology (ASCO) 2026 annual meeting will provide further data on imlunestrant (Inluriyo™) and abemaciclib (Verzenio®), offering insights into their potential roles in the therapeutic landscape.
Endocrine therapy remains the primary systemic treatment for HR+/HER2- breast cancer, encompassing selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs). Despite initial efficacy, resistance to endocrine therapy frequently develops, necessitating the development of new agents and combination strategies.1 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as abemaciclib, have significantly improved outcomes in advanced HR+/HER2- breast cancer when combined with endocrine therapy.2 Oral SERDs, including imlunestrant, represent a newer class of agents designed to overcome limitations of intramuscular fulvestrant and improve patient convenience.3
What the ASCO 2026 Presentations Will Cover
The ASCO 2026 annual meeting will feature separate presentations on imlunestrant and abemaciclib. The presentation on imlunestrant (Inluriyo™) is expected to detail efficacy and safety data from ongoing clinical trials. Imlunestrant is an investigational oral SERD. Early phase studies have explored its activity in HR+/HER2- advanced breast cancer, including in patients previously treated with endocrine therapy.4 Specific data points to anticipate include objective response rates (ORR), clinical benefit rates (CBR), progression-free survival (PFS), and the safety profile, particularly gastrointestinal adverse events and QT prolongation, which can be concerns with oral SERDs.5 The context of the data, whether in the first-line, second-line, or later-line settings, and in specific patient subgroups, will be critical for interpretation.4
A separate presentation will focus on abemaciclib (Verzenio®). Abemaciclib is an oral CDK4/6 inhibitor approved for use in HR+/HER2- advanced or metastatic breast cancer in combination with endocrine therapy, and as adjuvant therapy in certain high-risk patients.6 The upcoming presentation may provide updated long-term follow-up data from pivotal trials, further subgroup analyses, or data from studies exploring novel combinations or expanded indications. For example, data on the duration of benefit, the incidence of late-onset toxicities, or outcomes in specific patient populations, such as those with visceral metastases or brain metastases, would be of interest.7 Abemaciclib is known for its distinct toxicity profile compared to other CDK4/6 inhibitors, with a higher incidence of diarrhoea and a lower incidence of neutropenia.8 Any new data on managing these toxicities or their long-term impact would be relevant for clinical practice.8
The presentations will likely include detailed statistical analyses, such as hazard ratios (HR) for PFS or overall survival (OS), confidence intervals (CI), and p-values, to quantify the observed treatment effects. Patient numbers (N) and baseline characteristics will be essential for assessing the generalisability of the findings. The specific trial designs, including primary and secondary endpoints, will dictate the scope of the data presented. For imlunestrant, data on its efficacy in patients with ESR1 mutations, a common mechanism of resistance to aromatase inhibitors, would be particularly relevant.9 For abemaciclib, any data clarifying its role in patients who have progressed on prior CDK4/6 inhibitors, or in combination with other targeted agents, would be important.10
Limitations of the presented data will likely include the typical constraints of conference presentations, which may not always provide the full detail available in peer-reviewed publications. The follow-up duration for imlunestrant trials may still be relatively short, limiting conclusions on long-term efficacy and safety. For abemaciclib, while extensive data exists, the focus of the new presentation will determine its specific limitations. Future research will need to integrate these findings into the broader context of existing therapies and ongoing trials to refine treatment algorithms for HR+/HER2- breast cancer.
The forthcoming ASCO 2026 presentations on imlunestrant and abemaciclib underscore the pharmaceutical industry's persistent focus on refining endocrine therapy for HR+/HER2- breast cancer. For clinicians, the imlunestrant data will be scrutinised for its precise efficacy in various lines of therapy and its safety profile, particularly in comparison to existing oral SERDs and intramuscular fulvestrant. The convenience of an oral formulation is undeniable for patients, but this must be weighed against any differences in efficacy or tolerability. If imlunestrant demonstrates a favourable risk-benefit profile, it could offer a valuable alternative, potentially shifting prescribing patterns away from less convenient agents, especially in community oncology settings where patient preference for oral medications is high.
Regarding abemaciclib, any new data, particularly long-term follow-up or subgroup analyses, will serve to solidify its already established role. Given its approval in both advanced and adjuvant settings, further insights into its sustained benefit or the management of its specific adverse events, such as diarrhoea, will be directly applicable to daily practice. Clinicians are already adept at managing CDK4/6 inhibitor toxicities, but nuanced data could lead to more individualised treatment strategies, potentially improving patient adherence and quality of life. The industry, particularly Eli Lilly, will be keen to reinforce abemaciclib's market position against competitors like palbociclib and ribociclib, highlighting any unique advantages or expanded indications.
Ultimately, these presentations contribute to an increasingly complex therapeutic landscape. While new agents and data are welcome, they also demand a higher degree of precision from clinicians in patient selection and treatment sequencing. The challenge for guideline bodies, such as ESMO and NCCN, will be to rapidly integrate these findings into updated recommendations, ensuring that the evidence-based benefits reach patients efficiently. For patients, these developments offer continued hope for improved outcomes and potentially more tolerable treatment options, though the financial implications of novel therapies remain a significant consideration for healthcare systems globally.
- The Pivot New data on imlunestrant and abemaciclib will be presented, potentially refining their clinical application in HR+/HER2- breast cancer.
- The Data Specific hazard ratios, progression-free survival, or overall survival data will be critical for evaluating clinical utility.
- The Action Clinicians should review the presented data to understand the precise patient populations and treatment settings where these agents demonstrate benefit.
ART-2026-138
Cite This Article
Team TLSFE. Inluriyo™ and verzenio® presentations at asco 2026. The Life Science Feed. Updated May 30, 2026. Accessed May 30, 2026. https://thelifesciencefeed.com/oncology/breast-neoplasms/news/inluriyo-verzenio-asco-2026.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Johnston SRD. Acquired resistance to endocrine therapy in breast cancer. Lancet Oncol. 2011;12(11):1068-1077.
2. Goetz MP, Toi M, Campone L, et al. MONARCH 3: Abemaciclib as Initial Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.
3. Bidard F-C, Kaklamani VG, Neven P, et al. Elacestrant (oral SERD) versus standard endocrine therapy for ER+/HER2- advanced breast cancer: Results from the randomised phase 3 EMERALD trial. J Clin Oncol. 2022;40(17_suppl):LBA510.
4. Jhaveri K, et al. A Phase 1/2 Study of Imlunestrant (LY3484356), an Oral Selective Estrogen Receptor Degrader (SERD), in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer. Cancer Res. 2022;82(4_suppl):P1-17-02.
5. Bardia A, et al. GDC-9545 (Giredestrant) in ER-Positive, HER2-Negative Advanced Breast Cancer: Results From a Phase 1 Study. J Clin Oncol. 2021;39(15_suppl):1010.
6. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed on Endocrine Therapy. J Clin Oncol. 2017;35(32):3616-3626.
7. Rugo HS, et al. MONARCH 3: Abemaciclib as Initial Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer: 5-Year Update. J Clin Oncol. 2022;40(16_suppl):1001.
8. Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 Inhibitors in Breast Cancer: A Review. Curr Oncol Rep. 2020;22(1):1.
9. Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016;34(25):2968-2976.
10. Tolaney SM, et al. Abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer progressing on prior CDK4/6 inhibitor therapy: a phase 2 study. J Clin Oncol. 2023;41(16_suppl):1004.
